Skip to main content

Table 3 Comparison of shoulder ratings before and 6 weeks after ESWT/sham treatment in the study or placebo groups

From: Short-term outcomes of extracorporeal shock wave therapy for the treatment of chronic non-calcific tendinopathy of the supraspinatus: a double-blind, randomized, placebo-controlled trial

CMS ESWT PLACEBO P value1
PAIN    
Baseline 2.72 ± 2.61 (0-5) 3.33 ± 2.5 (0-5) 0.592
6 weeks 8.18 ± 3.37 (5-15) 4.44 ± 3.9 (0-10) 0.045
P value2 0.006 0.414  
ADL    
Baseline 10.27 ± 3.28 (5-18) 11.55 ± 4.21 (6-18) 0.378
6 weeks 15.1 ± 3.83 (7-20) 11 ± 5.48 (2-20) 0.068
P value2 0.01 0.674  
ROM    
Baseline 16.18 ± 4.68 (10-24) 16.67 ± 8.36 (2-26) 0.878
6 weeks 27.27 ± 8.5 (12-40) 17.1 ± 9.06 (8-32) 0.038
P value2 0.006 0.618  
POWER    
Baseline 13.27 ± 5.4 (5-20) 10.11 ± 3.18 (5-15) 0.170
6 weeks 13.36 ± 4.3 (7-18) 10.55 ± 4.21 (6-19) 0.174
P value2 0.834 0.726  
TOTAL    
Baseline 42.45 ± 9.83 (29-61) 41.67 ± 12.53 (20-57) 0.970
6 weeks 64 ± 16.6 (32-87) 43.11 ± 19.16 (18-70) 0.018
P value2 0.004 0.368  
  1. The values are given as mean ± standard deviation (range).
  2. 1 Comparison between treatment and control group both before and after treatment (Mann-Whitney U- test).
  3. 2 Comparison between before and after treatment within each group (Wilcoxon test).
  4. ESWT, indicates extracorporeal shock wave therapy; ADL, activity of daily living; ROM, range of motion; CMS, Constant and Murley Score.